Daratumumab: First Global Approval

Drugs

Volumn 76, Issue 2, 2016, Pages 275-281

  McKeage, Kate ^a  

^a NONE   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DARATUMUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ALLERGIC RHINITIS; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER FATIGUE; CENTRAL VOLUME OF DISTRIBUTION; DIARRHEA; DRUG CLEARANCE; DRUG HALF LIFE; DYSPNEA; FEVER; HUMAN; MULTIPLE MYELOMA; NEUTROPENIA; PHARMACODYNAMICS; STEADY STATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; PHASE 2 CLINICAL TRIAL (TOPIC);

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; MULTIPLE MYELOMA;

EID: 84954377172     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-015-0536-1     Document Type: Article

References (25)

1. Janssen Biotech Inc. Darzalex™ (daratumumab): prescribing information. 2015. http://www.accessdata.fda.gov/drugsatfda-docs/label/2015/761036s000lbl.pdf. Accessed 17 Dec 2015.
2. Genmab AS. Genmab enters worldwide agreement with Janssen for daratumumab [media release]. http://ir.genmab.com/releasedetail.cfm?ReleaseID=703394. Accessed 17 Dec 2015.
3. Phipps C, Chen Y, Gopalakrishnan S, et al. Daratumumab and its potential in the treatment of multiple myeloma: overview of the preclinical and clinical development. Ther Adv Hematol. 2015;6(3):120-7.
4. de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840-8.
5. US Food and Drugs Administration. FDA approves Darzalex for patients with previously treated multiple myeloma. 2015. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm472875.htm. Accessed 17 Dec 2015.
6. Janssen. Daratumumab receives breakthrough therapy designation in double refractory multiple myeloma from US Food and Drug Administration [media release]. http://www.investor.jnj.com/releasedetail.cfm?releaseid=761001. Accessed 17 Dec 2015.
7. Genmab. Genmab Announces US FDA approval of Darzalex™ (daratumumab) for multiple myeloma and updates financial guidance [media release]. http://ir.genmab.com/releasedetail.cfm?ReleaseID=942957. Accessed 17 Dec 2015.
8. Genmab. US FDA grants priority review for daratumumab for double refractory multiple myeloma [media release]. http://ir.genmab.com/releasedetail.cfm?ReleaseID=930345. Accessed 17 Dec 2015.
9. Janssen. Janssen submits marketing authorization application for daratumumab for European patients with heavily pretreated multiple myeloma [media release]. http://www.janssen.com/emea/sites/www-janssen-com-emea/files/dara-eu-filing-press-release-final.pdf. Accessed 17 Dec 2015.
10. Janssen. Janssen's new drug submission for daratumumab for treatment of multiple myeloma accepted for review by Health Canada [media release]. https://www.janssen.com/canada/sites/www-janssen-com-canada/files/daratumumab-filing-news-release.pdf. Accessed 17 Dec 2015.
11. Matas-Cespedes A, Vidal-Crespo A, Rodriguez V, et al. Daratumumab, a novel anti-CD38 monoclonal antibody shows anti-tumor activity in CLL and hampers leukemia-microenvironment interactions [abstract]. Blood. 2014;124:4680.
12. Halozyme Therapeutics. Halozyme Therapeutics enters a global collaboration with Janssen to develop and commercialize subcutaneous products using ENHANZE™ technology [media release]. http://www.halozyme.com/. Accessed 17 Dec 2014.
13. Overdijk MB, Verploegen S, Bogels M, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. mAbs. 2015;7(2):311-21.
14. Krejcik J, Casneuf T, Nijhof I, et al. Immunomodulatory effects and adaptive immune response to daratumumab in multiple myeloma [abstract]. Blood. 2015;126:3037.
15. van der Veer MS, de Weers M, van Kessel B, et al. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica. 2011;96(2):284-90.
16. Nijhof IS, Groen RWJ, Noort WA, et al. Preclinical evidence for the therapeutic potential of CD38-targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib. Clin Cancer Res. 2015;21(12):2802-10.
17. Nijhof IS, Lammerts van Bueren JJ, van Kessel B, et al. Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015;100(2):263-8.
18. Nijhof IS, Groen RW, Lokhorst HM, et al. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab. Leukemia. 2015;29(10):2039-49.
19. Chaulagain CP, Ma X, Doshi P, et al. Pre-clinical translational studies of daratumumab in patients with myeloma or AL amyloidosis undergoing autologous hematopoietic stem cell transplantation (SCT) [abstract no. 8587]. J Clin Oncol. 2015;33(15 Suppl 1).
20. Doshi P, Sasser AK, Axel A, et al. Daratumumab treatment in combination with CHOP or R-CHOP results in the inhibition or regression of tumors in preclinical models of non-hodgkins lymphoma [abstract no. P434]. Haematologica. 2014;99(Suppl 1):138-9.
21. Clemens PL, Yan X, Puchalski T, et al. Pharmacokinetics of daratumumab following intravenous infusion in relapsed or refractory multiple myeloma (MM) after prior proteasome inhibitor (PI) and immunomodulatory drug (IMiD) treatment [abstract no. PO-333]. In: 15th International Myeloma Workshop; 2015.
22. Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373(13):1207-19.
23. Lonial S, Weiss B, Usmani S, et al. Phase 2 study of daratumumab monotherapy in patients with >3 lines of prior therapy or double refractory multiple myeloma: 54767414MMY2002 (SIRIUS) [abstract no. S430]. Haematologica. 2015;100(Suppl 1):153.
24. Chapuy CI, Nicholson RT, Aguad MD, et al. Resolving the daratumumab interference with blood compatibility testing. Transfusion. 2015;55:1545-54.
25. Plesner T, Arkenau HT, Gimsing P, et al. Daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: updated results of a phase 1/2 study (GEN503) [abstract]. Blood. 2015;126:507.